U
UCB
Biopharmaceutical innovation for neurological and immunological severe diseases.
About UCB
UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, with approximately 9000 employees across 40 countries. The company focuses on developing treatments for severe diseases, particularly in the fields of neurology and immunology. UCB connects with patients and their families to gain insights that drive innovation and the development of new therapies. The company invests more than 25% of its revenue into scientific research to address unmet patient needs. UCB's business model revolves around the discovery, development, and commercialization of novel molecules, contributing to its €5.3 billion global revenue in 2023. The company serves patients worldwide, aiming to transform lives through its commitment to science and patient care.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1928
- Headquarters
- City of Brussels, Belgium
- Listing
- IPO 1999
- Employees
- 15,265
- Open positions
- 331
- Dealroom signal
- 48.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Charity, Intellectual Property, Retail, Biotechnology, Surgery, Neurology, EIT Health
- Technology
- Big Data, Deep Tech, Computer Vision
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 16 companies, latest Jun 2026
- Capital deployed
- $172M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2022 | $104M | — | Financière de Tubize SA | ↗ |
| SUPPORT PROGRAM✓Other financing | Jan 2019 | $0 | — | EIT Health | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for UCB is 120K monthly website visits, down 7.7% over the last three months. UCB's team grew 30.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cascador/moveUPBelgiumDigital care pathways, remote monitoring and real-world evidence for life sciences
$26Mvaluation
Candid TherapeuticsSan Diego, United StatesA clinical-stage biotech firm focused on advancing treatments for a range of immunological conditions
$2Bvaluation
Neurona TherapeuticsSouth San Francisco, United StatesCell therapy company focused on the development of breakthrough treatments for neurological disorders
$600Mvaluation
ImidomicsSan Rafael, United StatesFocuses on developing new medicines for immune-mediated inflammatory diseases
$66Mvaluation
BingliAntwerp, BelgiumDeveloping smart consultation preparation app, which interviews the patient ahead of the consultation so symptoms are accurately communicated to the doctor
$24Mvaluation
ZogenixEmeryville, United StatesDeveloping and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases
$1.5Bvaluation
Nile AILos Angeles, United StatesAI powered epilepsy care. We envision a future in which epilepsy is predictable. Our technology brings that future closer
$110Mvaluation
Handl TherapeuticsLeuven, BelgiumTreats complex neurodegenerative diseases to start addressing significant unmet medical needs in healthcare
→
Ra PharmaceuticalsCambridge, United StatesRa Pharma is developing Cyclomimetics™, a new drug class combining the properties and benefits of antibodies and small molecules
$2.3Bvaluation
CeribellMountain View, United StatesNovel approach to acquiring and interpreting electroencephalography (EEG) data
$265Mvaluation
StrideBioUnited StatesEngineered AAV vectors for gene therapy applications
$326Mvaluation
Syndesi TherapeuticsWavre, BelgiumDeveloper of a series of novel, procognitive SV2A modulators
$130Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Paul Capital
Financière de Tubize SA
Other known investors1 additional known investor
EIT Health
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about UCB on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See UCB’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.